000266099 001__ 266099
000266099 005__ 20240112171157.0
000266099 0247_ $$2pmc$$apmc:PMC10684607
000266099 0247_ $$2doi$$a10.1038/s41598-023-47765-7
000266099 0247_ $$2pmid$$apmid:38017278
000266099 0247_ $$2altmetric$$aaltmetric:156899282
000266099 037__ $$aDZNE-2023-01100
000266099 041__ $$aEnglish
000266099 082__ $$a600
000266099 1001_ $$aBarba, Lorenzo$$b0
000266099 245__ $$aSerum β-synuclein, neurofilament light chain and glial fibrillary acidic protein as prognostic biomarkers in moderate-to-severe acute ischemic stroke.
000266099 260__ $$a[London]$$bMacmillan Publishers Limited, part of Springer Nature$$c2023
000266099 3367_ $$2DRIVER$$aarticle
000266099 3367_ $$2DataCite$$aOutput Types/Journal article
000266099 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1701775238_15106
000266099 3367_ $$2BibTeX$$aARTICLE
000266099 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000266099 3367_ $$00$$2EndNote$$aJournal Article
000266099 520__ $$aWe aimed to assess the prognostic value of serum β-synuclein (β-syn), neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in patients with moderate-to-severe acute ischemic stroke. We measured β-syn, GFAP and NfL in serum samples collected one day after admission in 30 adult patients with moderate-to-severe ischemic stroke due to middle cerebral artery (MCA) occlusion. We tested the associations between biomarker levels and clinical and radiological scores (National Institute of Health Stroke Scale scores, NIHSS, and Alberta Stroke Program Early CT Score, ASPECTS), as well as measures of functional outcome (modified Rankin Scale, mRS). Serum biomarkers were significantly associated with ASPECTS values (β-syn p = 0.0011, GFAP p = 0.0002) but not with NIHSS scores at admission. Patients who received mechanical thrombectomy and intravenous thrombolysis showed lower β-syn (p = 0.029) und NfL concentrations (p = 0.0024) compared to patients who received only mechanical thrombectomy. According to median biomarker levels, patients with high β-syn, NfL or GFAP levels showed, after therapy, lower clinical improvement (i.e., lower 24-h NIHSS change), higher NIHSS scores during hospitalization and higher mRS scores at 3-month follow-up. Elevated serum concentrations of β-syn (p = 0.016), NfL (p = 0.020) or GFAP (p = 0.010) were significantly associated with 3-month mRS of 3-6 vs. 0-2 even after accounting for age, sex and renal function. In patients with moderate-to-severe acute ischemic stroke, serum β-syn, NfL and GFAP levels associated with clinical and radiological scores at different timepoints and were able to predict short- and middle-term clinical outcomes.
000266099 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000266099 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000266099 650_2 $$2MeSH$$aAdult
000266099 650_2 $$2MeSH$$aHumans
000266099 650_2 $$2MeSH$$abeta-Synuclein
000266099 650_2 $$2MeSH$$aBiomarkers
000266099 650_2 $$2MeSH$$aGlial Fibrillary Acidic Protein
000266099 650_2 $$2MeSH$$aInfarction, Middle Cerebral Artery
000266099 650_2 $$2MeSH$$aIntermediate Filaments
000266099 650_2 $$2MeSH$$aIschemic Stroke
000266099 650_2 $$2MeSH$$aNeurofilament Proteins
000266099 650_2 $$2MeSH$$aPrognosis
000266099 650_2 $$2MeSH$$aStroke: therapy
000266099 650_7 $$2NLM Chemicals$$abeta-Synuclein
000266099 650_7 $$2NLM Chemicals$$aBiomarkers
000266099 650_7 $$2NLM Chemicals$$aGlial Fibrillary Acidic Protein
000266099 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000266099 650_7 $$2NLM Chemicals$$aGFAP protein, human
000266099 650_7 $$2NLM Chemicals$$aSNCB protein, human
000266099 7001_ $$aVollmuth, Christoph$$b1
000266099 7001_ $$aAbu-Rumeileh, Samir$$b2
000266099 7001_ $$0P:(DE-2719)9002026$$aHalbgebauer, Steffen$$b3$$udzne
000266099 7001_ $$0P:(DE-2719)9001560$$aOeckl, Patrick$$b4$$udzne
000266099 7001_ $$aSteinacker, Petra$$b5
000266099 7001_ $$aKollikowski, Alexander M$$b6
000266099 7001_ $$aSchultz, Cara$$b7
000266099 7001_ $$aWolf, Judith$$b8
000266099 7001_ $$aPham, Mirko$$b9
000266099 7001_ $$aSchuhmann, Michael K$$b10
000266099 7001_ $$aHeuschmann, Peter U$$b11
000266099 7001_ $$aHaeusler, Karl Georg$$b12
000266099 7001_ $$aStoll, Guido$$b13
000266099 7001_ $$aNeugebauer, Hermann$$b14
000266099 7001_ $$aOtto, Markus$$b15
000266099 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/s41598-023-47765-7$$gVol. 13, no. 1, p. 20941$$n1$$p20941$$tScientific reports$$v13$$x2045-2322$$y2023
000266099 8564_ $$uhttps://pub.dzne.de/record/266099/files/DZNE-2023-01100.pdf$$yOpenAccess
000266099 8564_ $$uhttps://pub.dzne.de/record/266099/files/DZNE-2023-01100.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000266099 909CO $$ooai:pub.dzne.de:266099$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000266099 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002026$$aExternal Institute$$b3$$kExtern
000266099 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001560$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000266099 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000266099 9141_ $$y2023
000266099 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000266099 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2022$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:11:06Z
000266099 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:11:06Z
000266099 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000266099 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000266099 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:11:06Z
000266099 9201_ $$0I:(DE-2719)5000073$$kAG Öckl$$lTranslational Mass Spectrometry and Biomarker Research$$x0
000266099 980__ $$ajournal
000266099 980__ $$aVDB
000266099 980__ $$aUNRESTRICTED
000266099 980__ $$aI:(DE-2719)5000073
000266099 9801_ $$aFullTexts